Physician profile
Adriel Perez
NPI 1083276158
$9,926.92
in general payments reported to CMS, 2019-2025
37 companies · $608 in 2025
The $608 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,831 · 2022: $3,163 · 2023: $1,084 · 2024: $1,241 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.15 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,421.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Insulet Corporation | $1,366.87 | 2021-2025 | Omnipod |
| Lilly USA, LLC | $1,035.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $723.50 | 2021-2025 | Jardiance, Synjardy |
| Ibsa Pharma INC. | $673.18 | 2021-2024 | Tirosint, Licart, Tirosint |
| Xeris Pharmaceuticals, INC. | $648.59 | 2021-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $419.37 | 2021-2022 | |
| Amarin Pharma, INC. | $404.12 | 2021-2022 | |
| Amgen INC. | $402.24 | 2021-2025 | Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $381.75 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $288.09 | 2021-2022 | |
| Corcept Therapeutics | $286.91 | 2021-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $269.11 | 2021-2025 | Unithroid |
| Edwards Lifesciences Corporation | $153.53 | 2025 | |
| Tandem Diabetes Care, INC. | $130.83 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriel Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.